EP0276279A4 - Composition et procede d'immunisation contre des agents pathogenes viraux du sida et de l'arc. - Google Patents

Composition et procede d'immunisation contre des agents pathogenes viraux du sida et de l'arc.

Info

Publication number
EP0276279A4
EP0276279A4 EP19870905089 EP87905089A EP0276279A4 EP 0276279 A4 EP0276279 A4 EP 0276279A4 EP 19870905089 EP19870905089 EP 19870905089 EP 87905089 A EP87905089 A EP 87905089A EP 0276279 A4 EP0276279 A4 EP 0276279A4
Authority
EP
European Patent Office
Prior art keywords
aids
arc
matter
composition
against viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19870905089
Other languages
German (de)
English (en)
Other versions
EP0276279A1 (fr
Inventor
Patrick Kanda
Ronald C Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas Biomedical Research Institute
Original Assignee
Texas Biomedical Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Biomedical Research Institute filed Critical Texas Biomedical Research Institute
Publication of EP0276279A1 publication Critical patent/EP0276279A1/fr
Publication of EP0276279A4 publication Critical patent/EP0276279A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19870905089 1986-07-21 1987-07-20 Composition et procede d'immunisation contre des agents pathogenes viraux du sida et de l'arc. Withdrawn EP0276279A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88874286A 1986-07-21 1986-07-21
US888742 1992-05-22

Publications (2)

Publication Number Publication Date
EP0276279A1 EP0276279A1 (fr) 1988-08-03
EP0276279A4 true EP0276279A4 (fr) 1990-01-08

Family

ID=25393799

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19870905089 Withdrawn EP0276279A4 (fr) 1986-07-21 1987-07-20 Composition et procede d'immunisation contre des agents pathogenes viraux du sida et de l'arc.

Country Status (5)

Country Link
EP (1) EP0276279A4 (fr)
JP (1) JPH01500432A (fr)
AU (1) AU7786387A (fr)
DK (1) DK149188A (fr)
WO (1) WO1988000471A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US5126399A (en) * 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
EP0525828A3 (en) * 1986-08-01 1993-02-24 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
CA1341285C (fr) * 1988-02-12 2001-08-14 Chang Yi Wang Peptides synthetiques servant a la detection d'anticorps de la proteine de surface gp120 du virus hiv, destines au diagnostic du sida, ainsi que d'etats pre-sidatiques, ou aux fins de vaccins
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
EP0362909A3 (fr) * 1988-08-26 1990-11-14 Akzo N.V. Polypeptides synthétiques immuno-actifs avec des anticorps VIH
ZA896410B (en) * 1988-08-27 1990-05-30 Akzo Nv Synthetic peptides immunochemically reactive with hiv-antibodies
AU640619B2 (en) * 1988-10-03 1993-09-02 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
IL94558A0 (en) * 1989-06-06 1991-03-10 Merck & Co Inc Conjugate immunogen for aids and vaccine and pharmaceutical compositions containing it
US6248574B1 (en) * 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
EP0448095A1 (fr) * 1990-03-21 1991-09-25 Wolf, Hans Joachim, Prof. Dr. Sous-région de la protéine ENV rétrovirale, séquences d'ADN codant pour celle-ci et compositions pour le diagnostic, la prévention ou la thérapie des infections rétrovirales
IL98845A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
FR2677654B1 (fr) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
DE4417742A1 (de) 1994-05-20 1995-11-23 Bayer Ag Nicht-systemische Bekämpfung von Parasiten
DE69938062T2 (de) 1998-12-31 2009-01-15 Novartis Vaccines and Diagnostics, Inc., Emeryville Modifizierte hiv env polypeptide
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US20030194800A1 (en) 2001-08-31 2003-10-16 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
JP2002533124A (ja) 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
US6659681B1 (en) 1999-02-10 2003-12-09 Traf Fix Devices, Inc. Laterally stable vertical panel system
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CN106257728B (zh) 2016-01-28 2018-01-12 中国科学院过程工程研究所 一种生产3.5价高纯钒电解液的系统及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214709A2 (fr) * 1985-09-11 1987-03-18 United Biomedical Inc. Peptide synthétique et procédé pour son utilisation dans la détection d'anticorps de HTLV-III, le diagnostic de SIDA et pré-SIDA et comme vaccin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214709A2 (fr) * 1985-09-11 1987-03-18 United Biomedical Inc. Peptide synthétique et procédé pour son utilisation dans la détection d'anticorps de HTLV-III, le diagnostic de SIDA et pré-SIDA et comme vaccin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO8800471A1 *
The Journal of Biological Chemistry, Vol. 262, No. 12, April 25, 1987, pages 5768-5774, Baltimore, US; R.C. KENNEDY et al.: "Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope", whole article. *

Also Published As

Publication number Publication date
EP0276279A1 (fr) 1988-08-03
DK149188D0 (da) 1988-03-18
JPH01500432A (ja) 1989-02-16
WO1988000471A1 (fr) 1988-01-28
DK149188A (da) 1988-05-06
AU7786387A (en) 1988-02-10

Similar Documents

Publication Publication Date Title
EP0276279A4 (fr) Composition et procede d'immunisation contre des agents pathogenes viraux du sida et de l'arc.
GB8821049D0 (en) Method & composition for treatment & prevention of viral infections
PL268266A1 (en) The method of manufacture of proteins env virus aids
JPS6425800A (en) T-cell epitope of hepatities b virus nucleocapside protein
EP0318562A4 (fr) Procede d'inhibition selective d'hiv.
EP0414304A3 (en) Use of viruses against undesirable micro-organisms
AU1550983A (en) Blends of polyetherimide and organosiloxane-polycarbonate block copolymers
EP0232006A3 (en) Compositions for surface treatment, polymers therefor, and method of surface treatment
AR242561A1 (es) Procedimiento para la preparacion de clorhidrato de s-(-)-1-propil-2',6'-pipecoloxilidida opticamente sustancialmente puro y procedimiento
OA08608A (en) Pestical compositions and process for preparation thereof.
EP0608212A4 (fr) Procede de traitement des infections virales.
EP0249611A4 (fr) Virus t-lymphotrophique.
EP0256608A3 (en) Method of preparation and use of solid, phytoactive compositions
ZA903258B (en) Method of suppressing hiv infection
EP0610444A4 (fr) Procede de traitement de maladies virales.
AU7515287A (en) Methods and compositions for treating viral infections
AU6796287A (en) Method and composition for prophylaxis and treatment of viral infections
ZA87470B (en) Method and composition for prophylaxis and treatment of viral infections
HUT44439A (en) Process for inhibiting the reproduction of viruses and virus infections
GB2197200B (en) Methods and compositions for gas deodorisation
GB8717955D0 (en) Prevention & treatment of aids
AU7360387A (en) Bacteriocins used for anti-viral treatment (particularly aids)
ZA897105B (en) Method and composition for the treatment of viral infections
ZA888732B (en) Dsrna-based prevention of viral escape
EP0649847A3 (fr) Procédé et produits intermédiaires pour la préparation de (+)-hydantocidin et de ses analogues.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19880321

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KANDA, PATRICK

Inventor name: KENNEDY, RONALD, C.

Inventor name: SPARROW, JAMES T.

A4 Supplementary search report drawn up and despatched

Effective date: 19900108

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920201